TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06586567

Intervention type: OTHER
Intervention: Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas
Description: 2. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori

Intervention type: OTHER
Intervention: Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas
Description: 2. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori

Intervention type: OTHER
Intervention: Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas
Description: 2. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori
Study: NCT06597812

Intervention type: PROCEDURE
Intervention: Sevoflurane
Description: Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).

Intervention type: PROCEDURE
Intervention: Sevoflurane
Description: Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).
Study: NCT06596967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will be set to warm the water to 42°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will warm the water to 33°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
Study: NCT06590324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apabetalone
Description: 100-mg capsule, twice daily oral administration with meals
Study: NCT06595550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Powder milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no Whey protein
Description: Powder milk
Study: NCT06601881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Thoracic mobilization exercises will include:~1. Thoracic Spine Extension exersice~2. Thoracic rotation exersice~3. Cat-Camel Exercise~4. Lateral Flexion of the Thoracic Spine~5. Muscules Psoas Stretching~6. Diaphragm Release Technique~Diaphragmatic Breathing Training will include:~1. Diaphragmatic Breathing~2. Crocodile Breathing Technique~3. Breathing with an exercise band~4. Pursed lip breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (placebo) group
Description: Placebo Thoracic mobilization exercises will include:~1. Placebo Thoracic Spine Extension exersice~2. Placebo Thoracic rotation exersice~3. Placebo Cat-Camel Exercise~4. Placebo Lateral Flexion of the Thoracic Spine~5. Placebo Muscules Psoas Stretching~6. Placebo Diaphragm Release Technique~Placebo Diaphragmatic Breathing Training will include:~1. Placebo Diaphragmatic Breathing~2. Placebo Crocodile Breathing Technique~3. Placebo Breathing with an exercise band~4. Placebo Pursed lip breathing
Study: NCT06593301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training
Description: Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training
Description: Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)
Study: NCT06587152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Surgery with the Cornerstone Surgical Robot.
Study: NCT06596590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
Study: NCT06593964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermosensitive Nanogel Embolic Agent
Description: Thermosensitive Nanogel Embolic Agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermosensitive Nanogel Embolic Agent
Description: Thermosensitive Nanogel Embolic Agent
Study: NCT06586073

Intervention type: OTHER
Intervention: cosmetic products
Description: All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream.
Study: NCT06590948

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced ultrasound
Description: contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced ultrasound
Description: contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system
Study: NCT06595849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week feeling tone intervention program
Description: Participants will take part in a 4-week mindfulness of feeling tone intervention program taught by a registered mindfulness teacher, who is also a registered clinical psychologist. The intervention program includes 4 sessions, with each session lasting for about 2 hours. The program is taught in Cantonese, in a group setting, live online (via Zoom). Participants will practice meditation practices during the session, explore themes of the week, review and explore their meditation experiences. They will also practice meditation practices daily for at least 30 minutes at home, with meditation audio recordings provided by the teacher.
Study: NCT06598267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SASI
Description: single anastomosis sleeve ileal bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RYGB
Description: Roux-en-Y gastric bypass
Study: NCT06596746

Intervention type: OTHER
Intervention: Observation
Description: In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years

Intervention type: OTHER
Intervention: Observation
Description: In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
Study: NCT06592469

Intervention type: PROCEDURE
Intervention: Ureteroscopy
Description: URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter

Intervention type: PROCEDURE
Intervention: Ureteroscopy
Description: URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter
Study: NCT06601920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest healing activities
Description: The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest healing activities
Description: The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest healing activities
Description: The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest healing activities
Description: The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.
Study: NCT06602115

Intervention type: OTHER
Intervention: Observational study, no interventions involved
Description: Observational study, no interventions involved

Intervention type: OTHER
Intervention: Observational study, no interventions involved
Description: Observational study, no interventions involved
Study: NCT06598956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ05105
Description: TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ05105
Description: TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ05105
Description: TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ05105
Description: TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
Study: NCT06601309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
Description: Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
Description: Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
Study: NCT06601283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitmain C plus herbal medicine
Description: nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Study: NCT06590753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: osseodensification bur
Description: osseodensification bur

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: osseodensification bur
Description: osseodensification bur
Study: NCT06598683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional
Description: ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training
Study: NCT06612944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation
Description: 1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1
Study: NCT06591546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescoping nail
Description: The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc.
Study: NCT06604338

Intervention type: DIAGNOSTIC_TEST
Intervention: Exome test
Description: An exome will be performed on the participants of RPL group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota analysis
Description: A cervical microbiota analysis will be performed in the RPL and control groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota analysis
Description: A cervical microbiota analysis will be performed in the RPL and control groups.
Study: NCT06600438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slow-SPEED app
Description: Gamified motivational smartphone app

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slow-SPEED app
Description: Gamified motivational smartphone app
Study: NCT06585995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol) supplementation
Description: This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol) supplementation
Description: This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses
Study: NCT06586502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model of Care
Description: The intervention described in the RECOVER study involves developing, implementing, and evaluating a comprehensive Model of Care for childhood cancer survivors. This model, known as the RECOVER Model of Care, integrates digital health solutions and is co-designed with input from childhood cancer survivors, caregivers, and clinical experts. The intervention aims to address the long-term and late effects of cancer treatment by providing continuous, risk-based, interdisciplinary care. It includes steps such as identifying patients nearing the end of treatment, conducting health assessments, creating personalized care plans, and coordinating follow-up care through digital platforms. The study will assess the feasibility, acceptability, and effectiveness of this model in improving the quality of life and care experience for survivors and their families.